Journals / Bezmiâlem Science / 2019 / Cilt: 7 - Sayı: 4

Is İt Possible to Diagnose Endometrium Cancer with the Levels of Prolactin, Eotaxin, E-selectin and Ca 125?

Endometriyum Kanserini Prolaktin, Eotaksin, E-selektin ve Ca 125 Değerlerinden Tanıyabilir Miyiz?

Pages
281–285
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is currently no marker to distinguish EC from benign uterine pathologies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study to evaluate possible serum markers for distinction of endometrial carcinoma (EC) from benign uterine gynecologic diseases.
📊
Key Findings & Data:Methods: The study group consisted of 65 patients who were diagnosed with histologically confirmed EC were compared with 65 women who had operation indication for benign uterine diseases with fasting blood serum levels which were taken prior to surgery in terms of prolactin, eotaxin, e-selectin and Ca 125 concentrations.
💡
Conclusion & Impact:There is currently no marker to distinguish EC from benign uterine pathologies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study to evaluate possible serum markers for distinction of endometrial carcinoma (EC) from benign uterine gynecologic diseases. Methods: The study group consisted of 65 patients who were diagnosed with histologically confirmed EC were compared with 65 women who had operation indication for benign uterine diseases with fasting blood serum levels which were taken prior to surgery in terms of prolactin, eotaxin, e-selectin and Ca 125 concentrations. Results: Serum prolactin (20.7±18 and 16.2±13), eotaxin (219.4±95 and 205.15±80) and e-selectin (67.2±29 and 61.5±29) levels were not significantly different between EC and the other group (p>0.05). Ca 125 levels (36.6±40 and 18.8±9) were significantly higher in EC group when compared with the benign uterine patology group (p<0.05). Conclusion: Although serum levels of prolactin, eotaxin, e-selectin were higher in EC group, those were not statistically significant. Although, serum Ca 125 levels were siginificantly higher in EC group, diagnostic role of Ca 125 is limited. There is currently no marker to distinguish EC from benign uterine pathologies.

Özet

Amaç: Endometriyum kanserini (EK) diğer benign uterus patolojilerden ayırt etme de kullanılabilecek serum belirteçlerinin araştırılmasıdır. Yöntemler: Çalışma grubu olan histolojik olarak EK tanısı almış 65 hasta ile, benign uterin patolojiler nedeniyle operasyon endikasyonu alan 65 hastadan alınan ameliyat sabahı açlık kan örnekleri serumlarında prolaktin, eotaksin, E-selektin ve Ca 125 seviyeleri çalışıldı ve iki grup arasında bu seviyeler karşılaştırıldı. Bulgular: EK tanısı almış hastalar ile benign patolojileri olan hastaların serumları mukayese edildiğinde; serum prolaktin (20,7±18 ve 16,2±13), eotaksin (219,4±95 ve 205,15±80) ve E-selektin (67,2±29 ve 61,5±29) seviyeleri arasında anlamlı farklılık saptanmadı (p>0,05). EK’lilerde serum Ca 125 değerleri (36,6±40 ve 18,8±9) kontrol grubuna göre anlamlı olarak yüksek saptandı (p<0,05). Sonuç: Serum prolaktin, eotaksin ve E-selektin seviyesi benign uterus patolojileri olan hastalarla kıyaslandığında EK’li hastalarda daha yüksek saptansa da istatistiksel olarak anlamlı bir farklılık seviyesinde değildir. Ayrıca, serum Ca 125 seviyesi ise endometriyum kanserli hastalarda anlamlı olarak daha yüksek saptansa da, endometriyum kanserinin tanısında rolü kısıtlıdır. EK’yi benign uterus patolojilerinden ayırabilecek bir belirteç halen bulunmamaktadır.

🔖

Cite This Article

TAKMAZ, Ö., BERKMAN, S. (2019). Is İt Possible to Diagnose Endometrium Cancer with the Levels of Prolactin, Eotaxin, E-selectin and Ca 125?. Bezmiâlem Science, Cilt: 7 - Sayı: 4, 281–285. https://ajindex.com/articles/193228

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589-98
  2. Mercado C, Zingmond D, Karlan BY, Sekaris E, Gross J, Maggard- Gibbons M, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 2010;117:18-22
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30
  4. Smith HA, Kang Y. The metastasis-promoting roles of tumorassociated immune cells. J Mol Med (Berl) 2013;91:411-29
  5. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008;18:11-8
  6. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9576-82
  7. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743-50
  8. Zhang J, Lathbury LJ, Salamonsen LA. Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium. Biol Reprod 2000;62:404-11
  9. Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 2001;166:7571-8
  10. Ludwig RJ, Schon MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets 2007;11:1103-17
  11. Bock D, Philipp S, Wolff G. Therapeutic potential of selectin antagonists in psoriasis. Expert Opin Investig Drugs 2006;15:963- 79
  12. Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res 2006;130:125-40
  13. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 2006;85:1501-5
  14. Miralles C, Orea M, Espana P, Provencio M, Sanchez A, Cantos B, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150-4
  15. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000;75:264-5
  16. Ben-Jonathan N, Mershon JL,